Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Related Articles by Review for PubMed (Select 19723886)

1.

An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.

Viaud J, Peterson JR.

Mol Cancer Ther. 2009 Sep;8(9):2559-65. doi: 10.1158/1535-7163.MCT-09-0102. Epub 2009 Sep 1.

2.

p21-activated kinase inhibitors.

Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J.

Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Review.

PMID:
25034104
3.

p21-Activated kinase inhibitors: a patent review.

Crawford JJ, Hoeflich KP, Rudolph J.

Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Review.

PMID:
22404134
4.

Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.

Yi C, Maksimoska J, Marmorstein R, Kissil JL.

Biochem Pharmacol. 2010 Sep 1;80(5):683-9. doi: 10.1016/j.bcp.2010.03.012. Epub 2010 Mar 17. Review.

5.

Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Eswaran J, Li DQ, Shah A, Kumar R.

Clin Cancer Res. 2012 Jul 15;18(14):3743-9. doi: 10.1158/1078-0432.CCR-11-1952. Epub 2012 May 17. Review.

6.

p21-activated kinase 1: PAK'ed with potential.

Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP.

Oncotarget. 2011 Jun;2(6):491-6. Review.

7.

αC helix displacement as a general approach for allosteric modulation of protein kinases.

Palmieri L, Rastelli G.

Drug Discov Today. 2013 Apr;18(7-8):407-14. doi: 10.1016/j.drudis.2012.11.009. Epub 2012 Nov 27. Review.

PMID:
23195331
8.
9.

Protein kinase inhibitors: contributions from structure to clinical compounds.

Johnson LN.

Q Rev Biophys. 2009 Feb;42(1):1-40. doi: 10.1017/S0033583508004745. Epub 2009 Mar 19. Review.

PMID:
19296866
10.

Chemical inhibition through conformational stabilization of Rho GTPase effectors.

Deacon SW, Peterson JR.

Handb Exp Pharmacol. 2008;(186):431-60. doi: 10.1007/978-3-540-72843-6_18. Review.

PMID:
18491063
11.

A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.

Bogoyevitch MA, Fairlie DP.

Drug Discov Today. 2007 Aug;12(15-16):622-33. Epub 2007 Aug 2. Review.

PMID:
17706543
12.

New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.

Lamba V, Ghosh I.

Curr Pharm Des. 2012;18(20):2936-45. Review.

PMID:
22571662
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk